A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Tanox
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2013 Planned number of patients changed from 59 to 71 as reported by M.D. Anderson Cancer Center.
- 09 Jun 2006 New trial record.